Camber Capital Management LP Atara Biotherapeutics, Inc. Transaction History

Camber Capital Management LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$12.67 - $26.23 $17.7 Million - $36.7 Million	-1,400,000 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$7.53 - $14.93 $593,010 - $1.18 Million	-78,753 Reduced 5.33%	1,400,000 $20.4 Million
Q1 2020 May 15, 2020	SELL	$5.69 - $17.78 $8.37 Million - $26.2 Million	-1,471,247 Reduced 49.87%	1,478,753 $12.6 Million
Q3 2019 Nov 14, 2019	BUY	$12.03 - $19.94 $11.4 Million - $18.9 Million	950,000 Added 47.5%	2,950,000 $41.7 Million
Q1 2019 May 15, 2019	BUY	$28.4 - $41.74 $2.84 Million - $4.17 Million	100,000 Added 5.26%	2,000,000 $79.5 Million

Q4 2018 Feb 14, 2019	BUY	$30.9 - $42.97 $8.65 Million - $12 Million	280,000 Added 17.28%	1,900,000 $66 Million
Q2 2018 Aug 14, 2018	BUY	$35.15 - $51.45 $116,346 - $170,299	3,310 Added 0.2%	1,620,000 $59.5 Million
Q1 2018 May 15, 2018	BUY	$18.0 - $48.35 $19.5 Million - $52.3 Million	1,081,190 Added 201.9%	1,616,690 $63.1 Million
Q3 2017 Nov 14, 2017	BUY	$13.25 - $17.05 $7.1 Million - $9.13 Million	535,500	535,500 $8.86 Million

85M

18.4K

51.3K

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $710M
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Camber Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Camber Capital Management LP with notifications on news.